<ѻýҕl>First-Line Triplet Yields 'Striking' OS Result in Extensive-Stage SCLCѻýҕl> Median overall survival reached 19.3 months in Chinese trial Sep 11, 2023
<ѻýҕl>How the Chemotherapy Shortage Is Affecting Frontline Cliniciansѻýҕl> "How are we here in 2023 having some of these discussions?" bemoans gynecologic cancer expert Sep 08, 2023 video
<ѻýҕl>Microdevices for Glioma; Cervical Adenocarcinoma Test; Language Gaps and Cancer Careѻýҕl> News, features, and commentary about cancer-related issues Sep 07, 2023
<ѻýҕl>Prayer to Cure Cancer; Exercise for Sexual Dysfunction; Carb Intake and Cancerѻýҕl> News, features, and commentary about cancer-related issues Sep 01, 2023
<ѻýҕl>Novel KRAS Inhibitor Leads to Durable Responses in Multiple Tumor Typesѻýҕl> More than half of patients with NSCLC, more than a third of those with CRC responded to divarasib Aug 23, 2023
<ѻýҕl>Removing Race-Corrected Pulmonary Function Tests May Alter Lung Cancer Careѻýҕl> Path to eliminating these tests, while crucial, will be challenging, researchers say Aug 16, 2023
<ѻýҕl>Multi-Cancer Early Detection: 20th-Century Fiction Becomes Realityѻýҕl> These tests could soon become a valuable addition to current cancer screening tools Aug 01, 2023
<ѻýҕl>Immunotherapy Added to SABR Improves Event-Free Survival in Early NSCLCѻýҕl> Approach is "potentially practice-changing," editorialist says Jul 20, 2023
<ѻýҕl>Some NSCLC Patients on ICI Therapy Fare Worse With Proton Pump Inhibitor Useѻýҕl> But PFS, OS longer with ICIs plus chemotherapy among patients treated with PPIs Jul 11, 2023
<ѻýҕl>Pushback on Price Negotiation; Genetic Testing Lags; More Foreign Help for Shortagesѻýҕl> News, features, and commentary about cancer-related issues Jun 15, 2023
<ѻýҕl>Hooray! A Clearer Estimate of Your Risk for Death Is Hereѻýҕl> Researchers do the legwork to incorporate smoking status into NCI's "Know Your Chances" website Jun 09, 2023
<ѻýҕl>TTFields Therapy Yields OS Improvement in Second-Line NSCLCѻýҕl> However, device was not tested alongside current standard of care, expert points out Jun 08, 2023
<ѻýҕl>Checkpoint Blockade Stumbles in Advanced EGFR-Mutant NSCLCѻýҕl> "Immediate changes" needed to patient care to avoid unnecessary toxicity, says ASCO expert Jun 07, 2023
<ѻýҕl>Certain NSCLC Patients May Be Able to Stop Immunotherapy at 2 Yearsѻýҕl> Retrospective study finds no difference in OS between patients who stop and those who continue Jun 06, 2023
<ѻýҕl>New Data in NSCLC Bolster Support for Perioperative Immunotherapyѻýҕl> EFS benefit with pembrolizumab in KEYNOTE-671, but no OS benefit "yet," says investigator Jun 05, 2023
<ѻýҕl>New Standard in Operable EGFR-Positive Lung Cancerѻýҕl> "We should firmly close the door on one-size-fits-all treatment," says ASCO expert Jun 04, 2023
<ѻýҕl>Lung Cancer Screening Results Influence Follow-Up Adherenceѻýҕl> Study suggests groups to target for enhanced outreach to encourage regular screening May 25, 2023
<ѻýҕl>Drug Shortages Hit Oncology; Telemedicine Tops In-Person; Sniffing Out Lung Cancerѻýҕl> News, features, and commentary about cancer-related issues May 12, 2023
<ѻýҕl>'Potential' New Option for Operable NSCLCѻýҕl> Adding perioperative durvalumab to neoadjuvant chemo improved pCR rates, event-free survival Apr 17, 2023
<ѻýҕl>FDA Allows Lower Risk Designation for Snuff Productѻýҕl> The brand joins a limited few granted modified risk tobacco claims Mar 16, 2023
<ѻýҕl>'Winners' and 'Losers'; Mandated Sick Leave and Cancer Screening; More AI Advancesѻýҕl> News, features, and commentary about cancer-related issues Mar 03, 2023
<ѻýҕl>Cancer Drugs That Didn't Work; Another HIV Cure; Kiss of Success With Mistletoeѻýҕl> News, features, and commentary about cancer-related issues Feb 24, 2023
<ѻýҕl>AI Tool Forecasts Lung Cancer Risk From a Single CT Scanѻýҕl> Experts give high marks to performance of "Sybil" in predicting disease over 6 years Feb 07, 2023
<ѻýҕl>Risk Model-Based Lung Cancer Screening More Cost-Effective Than USPSTF Recsѻýҕl> Risk prediction models more sensitive than age-, smoking history-based methods Feb 07, 2023
<ѻýҕl>Bispecific Antibody Active in Relapsed/Refractory Small Cell Lung Cancerѻýҕl> A majority of patients obtained disease control with tarlatamab; responses proved durable Feb 01, 2023
<ѻýҕl>Immunotherapy Survival Gains 'Less Impressive' in Older Lung Cancer Patientsѻýҕl> Study finds median OS improvement of just 1 month for patients 75 and older Jan 26, 2023
<ѻýҕl>Xeljanz Cancer Risks Detailedѻýҕl> New paper provides full results from ORAL Surveillance trial Dec 07, 2022
<ѻýҕl>Lung Cancer Survival High for Patients With Early, Screen-Detected Tumorsѻýҕl> Two decades of I-ELCAP follow-up data show 80% lung cancer-specific survival rate Nov 28, 2022
<ѻýҕl>Lung Cancer Screening Programs Hit the Mark on Eligibility Criteriaѻýҕl> However, adherence to follow-up screening is "suboptimal" Oct 10, 2022
<ѻýҕl>FDA Grants First Tumor-Agnostic Approval for RET Fusion-Positive Cancersѻýҕl> Selpercatinib approved for advanced or metastatic solid tumors that progress on systemic therapy Sep 22, 2022
<ѻýҕl>KRAS Inhibitor Tops Docetaxel for Previously Treated NSCLCѻýҕl> "New second-line standard" in KRAS G12C-mutant disease, says study investigator Sep 13, 2022
<ѻýҕl>Survival Bump in Unfit NSCLC With First-Line Immunotherapyѻýҕl> Atezolizumab doubles OS at 2 years versus chemotherapy in those ineligible for platinum doublets Sep 12, 2022
<ѻýҕl>Combination Therapy Shows Promise for NSCLC That Progresses on Osimertinibѻýҕl> About half of patients responded to tepotinib plus osimertinib, but efficacy ceiling persists Sep 12, 2022
<ѻýҕl>Locking Down a Link Between Pollution and EGFR-Mutated Lung NSCLCѻýҕl> Study also shed lights on what may lead to lung cancer in never smokers Sep 11, 2022
<ѻýҕl>Study: Microwave Ablation for Lung Nodules Effective as Last Resortѻýҕl> Good option for patients who can't have surgery or radiotherapy, surgeon says Sep 08, 2022
<ѻýҕl>'Clinically Meaningful' Improvement in SCLC Patients With Pembrolizumab/Chemo Comboѻýҕl> Long-term follow-up shows continued survival benefit as first-line treatment Aug 11, 2022
<ѻýҕl>Triple Therapy Continues to Impress in Metastatic NSCLC With High-Risk Mutationsѻýҕl> Meaningful survival boosts in POSEIDON trial of front-line durvalumab, tremelimumab, and chemo Aug 10, 2022
<ѻýҕl>Survey: 77% of Women With Lung Cancer Report Sexual Dysfunctionѻýҕl> Results show need to integrate sexual health into care, researcher says Aug 09, 2022
<ѻýҕl>Neodjuvant Chemoimmunotherapy Takes Another Step Forward in Stage IIIA-B NSCLCѻýҕl> Phase II trial supports neoadjuvant nivolumab plus chemotherapy Aug 09, 2022
<ѻýҕl>New Data Bolster Atezolizumab as Adjuvant Tx in NSCLCѻýҕl> Overall survival benefit now demonstrated Aug 09, 2022